vs
Side-by-side financial comparison of Labcorp (LH) and TECK RESOURCES LTD (TECK). Click either name above to swap in a different company.
TECK RESOURCES LTD is the larger business by last-quarter revenue ($6.3B vs $3.5B, roughly 1.8× Labcorp).
Labcorp is a leading global life sciences and diagnostic testing firm that offers comprehensive clinical laboratory services, drug development support, and medical testing solutions for healthcare providers, pharmaceutical companies, and individual patients. It uses advanced scientific expertise and innovative technologies to deliver accurate, actionable health insights that support clinical decisions, accelerate new treatment development, and improve patient health outcomes globally.
Teck Resources Limited is a diversified natural resources company headquartered in Vancouver, British Columbia, that is engaged in mining and mineral development, including coal for the steelmaking industry, copper, zinc, and energy. Secondary products include lead, silver, gold, molybdenum, germanium, indium and cadmium. Teck Resources was formed from the amalgamation of Teck and Cominco in 2001.
LH vs TECK — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.5B | $6.3B |
| Net Profit | $164.7M | — |
| Gross Margin | 28.2% | 17.0% |
| Operating Margin | 7.6% | -3.0% |
| Net Margin | 4.7% | — |
| Revenue YoY | 5.6% | — |
| Net Profit YoY | 14.9% | — |
| EPS (diluted) | $1.98 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.5B | — | ||
| Q3 25 | $3.6B | $6.3B | ||
| Q2 25 | $3.5B | $3.4B | ||
| Q1 25 | $3.3B | $1.6B | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $3.3B | $4.6B | ||
| Q2 24 | $3.2B | $7.3B | ||
| Q1 24 | $3.2B | $3.8B |
| Q4 25 | $164.7M | — | ||
| Q3 25 | $261.1M | — | ||
| Q2 25 | $237.9M | — | ||
| Q1 25 | $212.8M | — | ||
| Q4 24 | $143.4M | — | ||
| Q3 24 | $169.3M | — | ||
| Q2 24 | $205.3M | — | ||
| Q1 24 | $228.0M | — |
| Q4 25 | 28.2% | — | ||
| Q3 25 | 28.8% | 17.0% | ||
| Q2 25 | 29.7% | 17.2% | ||
| Q1 25 | 28.3% | 10.4% | ||
| Q4 24 | 26.9% | — | ||
| Q3 24 | 27.6% | 20.7% | ||
| Q2 24 | 28.8% | 42.1% | ||
| Q1 24 | 28.2% | 44.0% |
| Q4 25 | 7.6% | — | ||
| Q3 25 | 11.1% | -3.0% | ||
| Q2 25 | 11.2% | -3.8% | ||
| Q1 25 | 9.7% | -2.2% | ||
| Q4 24 | 6.5% | — | ||
| Q3 24 | 7.7% | — | ||
| Q2 24 | 9.2% | 39.8% | ||
| Q1 24 | 10.1% | 49.0% |
| Q4 25 | 4.7% | — | ||
| Q3 25 | 7.3% | — | ||
| Q2 25 | 6.7% | — | ||
| Q1 25 | 6.4% | — | ||
| Q4 24 | 4.3% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 6.4% | — | ||
| Q1 24 | 7.2% | — |
| Q4 25 | $1.98 | — | ||
| Q3 25 | $3.12 | — | ||
| Q2 25 | $2.84 | — | ||
| Q1 25 | $2.52 | — | ||
| Q4 24 | $1.72 | — | ||
| Q3 24 | $2.00 | — | ||
| Q2 24 | $2.43 | — | ||
| Q1 24 | $2.69 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $532.3M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $8.6B | — |
| Total Assets | $18.4B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $532.3M | — | ||
| Q3 25 | $598.1M | — | ||
| Q2 25 | $647.3M | — | ||
| Q1 25 | $369.4M | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $265.1M | — | ||
| Q1 24 | $99.3M | — |
| Q4 25 | $8.6B | — | ||
| Q3 25 | $8.7B | — | ||
| Q2 25 | $8.5B | — | ||
| Q1 25 | $8.3B | — | ||
| Q4 24 | $8.1B | — | ||
| Q3 24 | $8.2B | — | ||
| Q2 24 | $8.0B | — | ||
| Q1 24 | $8.0B | — |
| Q4 25 | $18.4B | — | ||
| Q3 25 | $18.3B | — | ||
| Q2 25 | $18.1B | — | ||
| Q1 25 | $17.6B | — | ||
| Q4 24 | $18.4B | — | ||
| Q3 24 | $18.6B | — | ||
| Q2 24 | $16.7B | — | ||
| Q1 24 | $16.5B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $614.2M | — |
| Free Cash FlowOCF − Capex | $490.3M | — |
| FCF MarginFCF / Revenue | 13.9% | — |
| Capex IntensityCapex / Revenue | 3.5% | — |
| Cash ConversionOCF / Net Profit | 3.73× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.2B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $614.2M | — | ||
| Q3 25 | $387.2M | — | ||
| Q2 25 | $620.6M | — | ||
| Q1 25 | $18.5M | — | ||
| Q4 24 | $777.2M | — | ||
| Q3 24 | $277.3M | — | ||
| Q2 24 | $561.1M | — | ||
| Q1 24 | $-29.8M | — |
| Q4 25 | $490.3M | — | ||
| Q3 25 | $280.5M | — | ||
| Q2 25 | $542.7M | — | ||
| Q1 25 | $-107.5M | — | ||
| Q4 24 | $665.1M | — | ||
| Q3 24 | $161.5M | — | ||
| Q2 24 | $432.9M | — | ||
| Q1 24 | $-163.6M | — |
| Q4 25 | 13.9% | — | ||
| Q3 25 | 7.9% | — | ||
| Q2 25 | 15.4% | — | ||
| Q1 25 | -3.2% | — | ||
| Q4 24 | 20.0% | — | ||
| Q3 24 | 4.9% | — | ||
| Q2 24 | 13.4% | — | ||
| Q1 24 | -5.2% | — |
| Q4 25 | 3.5% | — | ||
| Q3 25 | 3.0% | — | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | 3.8% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 3.5% | — | ||
| Q2 24 | 4.0% | — | ||
| Q1 24 | 4.2% | — |
| Q4 25 | 3.73× | — | ||
| Q3 25 | 1.48× | — | ||
| Q2 25 | 2.61× | — | ||
| Q1 25 | 0.09× | — | ||
| Q4 24 | 5.42× | — | ||
| Q3 24 | 1.64× | — | ||
| Q2 24 | 2.73× | — | ||
| Q1 24 | -0.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
TECK
Segment breakdown not available.
